Table 1 Patients' characteristics
Raltitrexed | Raltitrexed+irinotecan | |
|---|---|---|
Number of patients | 19 | 19 |
Gender | ||
Male | 8 | 12 |
Female | 11 | 7 |
Median age in years (range) | 60 (40–74) | 63 (49–75) |
Karnofsky performance status (%) | ||
90–100 | 4 (21%) | 4 (21%) |
70–80 | 10 (53%) | 9 (47%) |
50–60 | 5 (26%) | 6 (32%) |
Prior surgery | ||
Whipple | 5 (26%) | 4 (21%) |
Palliative bypass | 4 (21%) | 6 (32%) |
Stent | 5 (26%) | 5 (26%) |
None | 5 (26%) | 4 (21%) |
Response to first-line chemotherapy a | ||
PR | 2 (11%) | 3 (16%) |
SD | 9 (47%) | 8 (42%) |
PD | 8 (42%) | 8 (42%) |
Sites of metastases | ||
Abdominal mass | 15 (79%) | 16 (84%) |
Liver | 14 (74%) | 12 (63%) |
Lung | 5 (26%) | 4 (21%) |
Spleen | 1 (5%) | 2 (11%) |
Adrenals | 1 (5%) | 1 (5%) |
Soft tissue | 2 (11%) | 3 (16%) |
Histological grading | ||
1 | 2 (11%) | 1 (5%) |
2 | 10 (53%) | 12 (63%) |
3 | 7 (37%) | 6 (32%) |
